Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Patrick C. May, PH.D.

Patrick C. May, PH.D.

President at ADvantage Neuroscience Consulting LLC

Connect with Patrick C. May, PH.D. on LinkedIn
Follow Patrick C. May, PH.D. on Twitter

About the author: Dr. May is an independent pharmaceutical consultant focusing on drug discovery in Alzheimer’s disease and related neurodegenerative diseases. He retired from Eli Lilly and Co. in 2014 as a Senior Research Fellow in the Neuroscience Discovery Research area. During his 25 year career at Lilly, he helped to build and establish one of industry’s leading Alzheimer’s disease drug discovery programs. Together with his discovery colleagues, he has delivered numerous candidates for clinical testing in AD and other neurologic disorders and cancer. He has authored or co-authored over 100 research articles and book chapters and has chaired and/or served on biomedical peer review panels for the Alzheimer’s Association, NIA AD Drug Discovery UO1 SEP, the Alzheimer’s Society of Canada, the European Centers of Excellence for Neurodegeneration, and Weston Brain Institute. Since retiring from Lilly, Dr. May founded ADvantage Neuroscience Consulting LLC in order to offer his unique perspective to drug discovery efforts in academia and pharma. In his free time he enjoys traveling, playing piano and golf.

Posts by Patrick C. May, PH.D.

Review of Alzheimer’s Association International Conference (AAIC16) Part 1: Focus on Tau

Posted on August 10th, 2016 in Pharma R&D

I have just returned from the Alzheimer’s Association International Conference (AAIC16) in Toronto, Canada. Toronto is a beautiful cosmopolitan city and a perfect setting for scientists from across the globe to come and share their latest research on Alzheimer’s disease. (more…)

  1. 1
  2. 2